What we know

A preprint from Divergence Labs reports the design of an IgE disruptor antibody aimed at treating food allergies. This antibody was created using Claude, an AI system for antibody design. Laboratory tests show that the antibody can block IgE-mediated allergic responses in vitro, suggesting potential for therapeutic use. Divergence Labs used Claude, an AI model, to design an antibody that disrupts IgE. The antibody demonstrated the ability to block IgE-driven allergic reactions in laboratory experiments.

Why it matters

IgE antibodies are key drivers of allergic reactions, including those triggered by food. Developing therapies that can interrupt IgE’s activity is a major goal in allergy treatment. The use of AI like Claude to design such antibodies could accelerate discovery and improve precision.

What is still unknown

No independent tests have confirmed the antibody’s effectiveness or safety. Details about the AI system’s design process, supported languages, or plans for clinical development and broader release remain undisclosed. The preprint does not specify timelines for further validation or potential commercialization.